Skip to main content

Table 4 Base case results

From: Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

  Current scenario tested No-testing Difference
Cost of testing € 3,613,701 € 0 € + 3, 613, 701
Cost of treatment € 854,664,411 € 806,959,058 € + 47, 705, 353
Total costs € 858,278,111 € 806,959,058 € + 51, 319, 053
LY 21.233,59 16.173,45 + 5060.14
QALYs 14.654,68 10.748,05 + 3906.64
ICER (€/LY gained) € 10,142/LY
ICUR (€/QALY gained) € 13,136/QALY
  1. LY life years, QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio, ICUR incremental cost-utility ratio